Navigation Links
Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
Date:11/21/2013

p>The DESSOLVE I trial, the first clinical assessment of safety and efficacy of the MiStent SES®, treated thirty patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent. Subjects were enrolled across five study centers in New Zealand, Australia and Belgium. Three independent subgroups of 10 patients each were evaluated using angiography, IVUS and OCT at three time points: four, six and eight months. The primary efficacy endpoint was in-stent late lumen loss. Safety was assessed by incidence of MACE and presence of strut coverage with tissue within the treated artery at each time point. William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium and John Ormiston,  M.B.Ch.B., Mercy Angiography Unit, Auckland, New Zealand are co-principal investigators for this trial.

The DESSOLVE II CE (Conformite Europeenne) Mark trial is a randomized, multi-center study of patients with documented stable or unstable angina pectoris. The primary endpoint is superiority of the MiStent SES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured by an independent angiography core laboratory in de novo coronary lesions in vessels ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm length stent. The DESSOLVE II study completed enrollment of 184 patients in July 2011. Data analysis confirms that DESSOLVE II met all study objectives, demonstrated a competitive in-stent late lumen loss, and achieved strong signal of safety.

About Micell Technologies Inc.

Micell Technologies is enhancing the performance of cardiovascular medical devices with innovative drug-delivery system
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PaperFree Pharmacy Generation 3 Hits the Market
2. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
3. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
4. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
5. Automation is Revolutionizing White Cell Differential Analysis; New Whitepaper Details How
6. Angelus says Home Office Banning Legal High Benzo Fury is "Papering over the Cracks"
7. RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care
8. 150,000 Medical Professionals Stay Paperless with Practice Fusion
9. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
10. TechMed Charts: New Specialists in Thermal Papers and Supplies for Patient Monitoring and Process Control
11. Disinfectant Qualification Questions are Answered for Sterile Drug Manufacturers in New White Paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:7/24/2014)... KS (PRWEB) July 25, 2014 ... can be affected by the width of the alveolar ... hold the implant. A variety of methods exist, each ... subsequent augmentation techniques. The ridge-split graft is highlighted as ... The Journal of Oral Implantology offers a comparison ...
(Date:7/24/2014)... 25, 2014 Dr. Henry H. Ting, ... quality, has been appointed senior vice president and chief ... In his new role, he will oversee the hospital's ... has successfully led quality initiatives and interprofessional teams at ... teams for the Door-to-Balloon Alliance, a collaboration of more ...
(Date:7/24/2014)... Preventive Services Task Force recently recommended computerized tomography ... for cancer, but a potential problem with CT ... on the screening test, only to be deemed ... concern that this high false-positive rate will cause ... of National Lung Screening Trial participant responses to ...
(Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... Nov. 3 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the ... development of novel antibiotics for the treatment of,antibiotic-resistant ... Chief Executive Officer, is scheduled to present at ... Monday, November 10,2008 at 2:00pm EST. The conference ...
... TSX: BMR, TORONTO, Nov. 3 /PRNewswire-FirstCall/ - ... development and,commercialization of cancer therapies, announced today that ... of the Company, will present a,corporate update at ... being held in New York City from November ...
... Most frequent tumor sites were cervix, head and neck, ... -- An estimated 25,000 cases of cancers associated with ... District of Columbia between 1998 and 2003, U.S. officials ... that includes more than 100 different types, more than ...
... study comparing cancer rates of liver transplant patients to ... recipients face increased risks of developing cancer, especially non-Hodgkin,s ... the first year of follow-up and among younger transplant ... of Liver Transplantation , a journal by John ...
... new studies conclude that a review which claimed that homeopathy ... was seriously flawed. , George Lewith, Professor of ... indication of which trials were analysed nor of the various ... scientific practice. If we presume that homeopathy works for some ...
... genetic vulnerability , , MONDAY, Nov. 3 (HealthDay News) ... States that get a lot of precipitation appear to ... study suggests. , Because these children may spend more ... atmosphere to the ground, they might be exposed to ...
Cached Medicine News:Health News:Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 3Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:Liver transplant recipients have higher cancer risk 2Health News:New evidence for homeopathy 2Health News:Rainier Spots Show Higher Autism Rates 2Health News:Rainier Spots Show Higher Autism Rates 3Health News:Rainier Spots Show Higher Autism Rates 4
... lens, doctors have to make a trade off ... Now, with the Digital Wide Field lens ... both in one lens. This lens provides ... non-contact lens paired with the higher magnification required ...
... The Stryker Wedge Suture Anchors are titanium ... and styles. The Wedge anchors are simple ... and OR staff. The following sizes and ... Suture, 5.0mm Single Eyelet 2 Sutures, 5.0mm ...
... Suture Anchor is a 3.0mm single loaded ... (PLLA). The anchor barb catches on the ... until it "breaks" free. The small size ... also frequently used in rotator cuff repair ...
... absorbable co-polymer synthesized from all-natural ingredients: ... acid. Unlike the homopolymers in common ... (PLLA) or 100% poly-glycolic acid (PGA), ... crystallinity), meaning that its degradation is ...
Medicine Products: